Results from a multi-center prospective validation study have confirmed the sensitivity and high negative predictive value of a gene expression test marketed by Veracyte to identify patients whose thyroid nodules are likely to be benign and who can thus avoid further diagnostic surgery or complete thyroid removal with lifelong hormone replacement therapy.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.